moderate - Elective orthopedic procedures exhibit cyclical sensitivity as patients defer non-urgent surgeries during economic uncertainty or when out-of-pocket costs rise. However, SI joint fusion addresses chronic pain (average 5+ years of symptoms), creating pent-up demand that partially insulates volumes. Hospital capital budgets and ASC procedure scheduling are more sensitive to GDP and employment trends than emergency care. Estimate 60-70% correlation with broader elective surgery volumes.

Rising rates pressure valuation multiples for unprofitable growth companies, as SI-BONE's negative FCF makes it sensitive to discount rate changes. Higher rates also increase financing costs for hospitals and ASCs, potentially delaying capital equipment purchases or tightening procedure approval processes. Patient financing for out-of-pocket costs becomes more expensive, though SI joint fusion typically has lower patient cost-sharing than spinal fusion alternatives. Primary impact is multiple compression rather than fundamental demand destruction.

growth - Investors focus on revenue CAGR (20%+ required), market penetration in underpenetrated SI joint dysfunction diagnosis (estimated <5% of addressable patients currently treated surgically), and path to profitability by 2027-2028. The stock attracts growth-at-reasonable-price investors given 3.4x P/S vs. 5-8x for high-growth medtech peers, but requires conviction in clinical evidence and reimbursement sustainability. Not suitable for value or income investors given negative earnings and no dividend.